Literature DB >> 8005190

Topical formulations of fluocinolone acetonide. Are creams, gels and ointments bioequivalent and does dilution affect activity?

H Y Gao1, A Li Wan Po.   

Abstract

The study was done in healthy volunteers to investigate the vasoconstrictor activity of three commercially available formulations of fluocinolone acetonide (Synalar gel, cream and ointment) and to determine whether they were bioequivalent. The influence of dilution of the cream formulation on activity was also examined. Twenty mg of each topical formulation was applied, followed by occlusion for 6 h, and the potency was evaluated by measuring the vasoconstrictor effect using tristimulus colour analysis. The cream formulation was more potent than the ointment, with the gel having intermediate strength. Dilution did not significantly reduce activity. While choice of an appropriate topical corticosteroid formulation largely depends on the nature of the lesions, this study has shown that different formulations of nominally the same concentration have different potencies; dilution up to 1 in 10 produced no significant reduction in potency. The potency classification in the British National Formulary for formulations of Synalar may need revision.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8005190     DOI: 10.1007/BF00195919

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  14 in total

1.  Quantitative skin blanching assay of corticosteroid creams using tristimulus colour analysis.

Authors:  S Y Chan; A Li Wan Po
Journal:  J Pharm Pharmacol       Date:  1992-05       Impact factor: 3.765

2.  Topical therapy of psoriasis with fluocinolone acetonide.

Authors:  J R SCHOLTZ
Journal:  Arch Dermatol       Date:  1961-12

3.  Are generic formulations equivalent to trade name topical glucocorticoids?

Authors:  R B Stoughton
Journal:  Arch Dermatol       Date:  1987-10

4.  Comparative bio-availability of proprietary topical corticosteroid preparations; vasoconstrictor assays on thirty creams and gels.

Authors:  B W Barry; R Woodford
Journal:  Br J Dermatol       Date:  1974-09       Impact factor: 9.302

5.  Influence of vehicles on the topical activity of fluorometholone.

Authors:  J Tissot; P E Osmundsen
Journal:  Acta Derm Venereol       Date:  1966       Impact factor: 4.437

6.  Vehicle design for a new topical steroid, fluocinonide.

Authors:  J Ostrenga; J Haleblian; B Poulsen; B Ferrell; N Mueller; S Shastri
Journal:  J Invest Dermatol       Date:  1971-05       Impact factor: 8.551

7.  The same glucocorticoid in brand-name products. Does increasing the concentration result in greater topical biologic activity?

Authors:  R B Stoughton; K Wullich
Journal:  Arch Dermatol       Date:  1989-11

8.  The stability of betamethasone-17-valerate in semi-solid bases.

Authors:  Y W Yip; L W Po
Journal:  J Pharm Pharmacol       Date:  1979-06       Impact factor: 3.765

9.  The clinical assessment of topical corticosteroid activity.

Authors:  L Wilson
Journal:  Br J Dermatol       Date:  1976-03       Impact factor: 9.302

10.  The use of mixtures of topical corticosteroids as a mechanism for improving total drug bioavailability: a preliminary report.

Authors:  B J Poulsen; Z T Chowhan; R Pritchard; M Katz
Journal:  Curr Probl Dermatol       Date:  1978
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.